Modified FOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab beyond first progression in advanced colorectal cancer: CCOG-0801 study. A phase I/II study of biweekly XELIRI plus bevacizumab ...
Abenacianine, a fluorescent imaging agent, aids in real-time tumor visualization during lung cancer surgeries, enhancing surgical precision and outcomes. Fast track designation by the FDA highlights ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Implementation of an endocrinology fast-track program may allow patients with poorly controlled ...
Researchers recently examined more than 1500 knee and hip replacement procedures conducted as part of a single institution’s fast-track protocol. At 1 year, patients in the fast-track program reported ...
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the U.S. Food & Drug Administration (FDA) has granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results